INCLINE VILLAGE, Nev. , May 2, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after market close.

INCLINE VILLAGE, Nev. , April 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 20, 2019 , at 3:00 p.m. Pacific Time for all stockholders of record on April 26, 2019 .

Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal,

INCLINE VILLAGE, Nev. , March 26, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, and Peter Garcia , PDL's chief financial officer, will present at the H.C. Wainwright & Co.

INCLINE VILLAGE, Nev. , March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December 31, 2018 : Financial Highlights Total revenues of $45.1 million for the 2018 fourth quarter and $198.1 million for

INCLINE VILLAGE, Nev. , March 12, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Peter Garcia , PDL's vice president and chief financial officer, will participate in a series of investor meetings at the 31 st Annual Roth Conference being held March

INCLINE VILLAGE, Nev. , March 7, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018 , on Thursday, March 14, 2019 , after market

INCLINE VILLAGE, Nev. , March 5, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, and Peter Garcia , PDL's chief financial officer, will present at the Cowen 39 th Annual Health Care

INCLINE VILLAGE, Nev. , March 4, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL", NASDAQ: PDLI) announces the U.S. commercial launch of an authorized generic of Tekturna ® , aliskiren hemifumarate 150 mg and 300 mg tablets.  The authorized generic has the same drug formulation as Tekturna.

INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City.  The session will be webcast live and will occur on Tuesday, November 27, 2018 , at

Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights Total revenues of $67.9

INCLINE VILLAGE, Nev. , Oct. 31, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018 , on Tuesday, November 6, 2018 , after market close.  PDL's management

INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will

INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York City. The session will be webcast

INCLINE VILLAGE, Nev. , Sept. 24, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block